<DOC>
	<DOC>NCT01813552</DOC>
	<brief_summary>This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety and tolerability of the study drugs when administered alone and in combination in healthy participants.</brief_summary>
	<brief_title>To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Read and signed the written informed consent form (ICF) after the nature of the study has been fully explained. All participants of childbearing potential must agree to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug. Pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>antiviral drugs</keyword>
	<keyword>liver</keyword>
</DOC>